Casas, MD, discusses a systematic review of recent trials examining objective response rate and adverse events of antibody drug conjugate (ADC) combinations in advanced urothelial cancer.

Results also show that reducing the Padcev dose at treatment initiation may benefit older patients with urothelial carcinoma, ...

Data on enfortumab vedotin plus pembrolizumab for advanced bladder cancer, along with updates on antibody-drug conjugates, ...

An important unanswered question is whether rechallenging patients with enfortumab vedotin plus pembrolizumab after prior ICI exposure remains effective. The authors hypothesized that enfortumab ...

Armando, a 71-year-old with an active lifestyle, was midway through a round of golf when a strange sensation crept into his abdomen after drinking water. It was just a fleeting moment; one he brushed ...

Neuropathy, skin rash, and hyperglycemia following enfortumab vedotin treatment were associated with improved PFS in ...

Dr Scott Tagawa discusses how dose adjustments can optimize the use of enfortumab vedotin in urothelial cancer.

Findings also suggested that an up-front dose reduction of enfortumab vedotin may benefit older patients with urothelial carcinoma.

GU ASCO annual meeting featured a urothelial carcinoma session and a discussant presentation by Dr. Elizabeth Plimack discussing two abstracts: “Adjuvant nivolumab vs placebo for high-risk ...

In the last decade, immunotherapy with PD-1/PD-L1 inhibitors has transformed the treatment of relapsed urothelial carcinoma (UC), the most common form of bladder cancer. Now, new data suggests new ...

Pfizer & Astellas’ Padcev plus Keytruda shows long-term efficacy in first-line treatment of locally advanced or metastatic urothelial cancer: New York Wednesday, February 12, 20 ...

It was there that a biopsy uncovered the truth: Armando had Stage 4 metastatic urothelial carcinoma (mUC), also known as advanced bladder ... Exploring PADCEV (enfortumab vedotin-ejfv) with ...